## Edgar Filing: CUMBERLAND PHARMACEUTICALS INC - Form 4

CUMBERLAND PHARMA Form 4 May 27, 2016	CEUTICALS IN	IC								
FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 child put abligations	STATES SEC V MENT OF CHA ursuant to Section (a) of the Public 30(h) of the	ANGES IN SECUE 16(a) of th Utility Hole	, D.C. 20 BENEFI RITIES the Securit ding Com	549 CCIA ies E	<b>L OW</b> xchang Act o	<b>NERSHIP OF</b> ge Act of 1934, f 1935 or Sectio	OMB Number: Expires: Estimated a burden hou response	rs per		
(Print or Type Responses)										
1. Name and Address of Reporting Herman James L	Symbo CUN	2. Issuer Name <b>and</b> Ticker or Trading Symbol CUMBERLAND PHARMACEUTICALS INC [CPIX]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) (First) 2525 WEST END AVENUE 950	of Earliest Transaction /Day/Year) /2016				Director      10% Owner        N Officer (give title      Other (specify below)         below)       below)         VP and Chief Compliance Office					
(Street) NASHVILLE, TN 37203	Filed(Month/Day/Year) App _X_					Applicable Line) _X_ Form filed by 0	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting			
	(7:5)					Person				
(City) (State)		able I - Non-I				quired, Disposed of		-		
1.Title of Security (Instr. 3)2. Transaction Da (Month/Day/Year)	tte 2A. Deemed r) Execution Date, any (Month/Day/Ye	Code ar) (Instr. 8)	4. Securi ion(A) or D (D) (Instr. 3,	ispose	d of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)			
Common 05/26/2016 Stock		F	3,840 (1)	D	\$ 4.51	38,744	D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	3. Transaction Date (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	7. Titl Amou Under Secur (Instr.	int of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Own Follo Repo Trans (Instr
		Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

## Edgar Filing: CUMBERLAND PHARMACEUTICALS INC - Form 4

## **Reporting Owners**

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Herman James L 2525 WEST END AVENUE, SUITE 950 NASHVILLE, TN 37203			VP and Chief Compliance Office				
Signatures							
James L. Herman by /s/ Michael Bonner as attorney-in-fact			05/27/2016				
<u>**</u> Signature of Reporting Person			Date				
<b>Explanation of Response</b>	es:						

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This transaction represents shares withheld by the Company to cover the tax withholding obligations for the vesting of 11,759 shares during May 2016.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.